The mitochondrial and autosomal mutation landscapes of prostate cancer.

BACKGROUND Prostate cancer (PCa) is the most common cancer in men. PCa is strongly age associated; low death rates in surveillance cohorts call into question the widespread use of surgery, which leads to overtreatment and a reduction in quality of life. There is a great need to increase the understanding of tumor characteristics in the context of disease progression. OBJECTIVE To perform the first multigenome investigation of PCa through analysis of both autosomal and mitochondrial DNA, and to integrate exome sequencing data, and RNA sequencing and copy-number alteration (CNA) data to investigate how various different tumor characteristics, commonly analyzed separately, are interconnected. DESIGN, SETTING, AND PARTICIPANTS Exome sequencing was applied to 64 tumor samples from 55 PCa patients with varying stage and grade. Integrated analysis was performed on a core set of 50 tumors from which exome sequencing, CNA, and RNA sequencing data were available. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Genes, mutated at a significantly higher rate relative to a genomic background, were identified. In addition, mitochondrial and autosomal mutation rates were correlated to CNAs and proliferation, assessed as a cell cycle gene expression signature. RESULTS AND LIMITATIONS Genes not previously reported to be significantly mutated in PCa, such as cell division cycle 27 homolog (Saccharomyces cerevisiae) (CDC27), myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3), lysine (K)-specific demethylase 6A (KDM6A), and kinesin family member 5A (KIF5A) were identified. The mutation rate in the mitochondrial genome was 55 times higher than that of the autosomes. Multilevel analysis demonstrated a tight correlation between high reactive-oxygen exposure, chromosomal damage, high proliferation, and in parallel, a transition from multiclonal indolent primary PCa to monoclonal aggressive disease. As we only performed targeted sequence analysis; copy-number neutral rearrangements recently described for PCa were not accounted for. CONCLUSIONS The mitochondrial genome displays an elevated mutation rate compared to the autosomal chromosomes. By integrated analysis, we demonstrated that different tumor characteristics are interconnected, providing an increased understanding of PCa etiology.

[1]  G. Pesole,et al.  Mitochondrial genomes gleaned from human whole-exome sequencing , 2012, Nature Methods.

[2]  J. Hicks,et al.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. , 2002, Cancer research.

[3]  Christian Ruiz,et al.  Advancing a clinically relevant perspective of the clonal nature of cancer , 2011, Proceedings of the National Academy of Sciences.

[4]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[5]  Jennifer R. Rider,et al.  The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[6]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[7]  L. Cavelier,et al.  Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[9]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[10]  Cesar M. Castro,et al.  Ultrasensitive Clinical Enumeration of Rare Cells ex Vivo Using a Micro-Hall Detector , 2012, Science Translational Medicine.

[11]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[12]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[13]  E. Montgomery,et al.  Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.

[14]  F. Kronenberg,et al.  Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. , 2010, American journal of human genetics.

[15]  D. Gisselsson,et al.  Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Beal,et al.  High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. , 2002, Human molecular genetics.

[17]  M. Stratton,et al.  Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.

[18]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[19]  T. Kunkel,et al.  DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Samuels,et al.  Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors , 2012, BMC Cancer.

[21]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[22]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[23]  M. Goyns Genes, telomeres and mammalian ageing , 2002, Mechanisms of Ageing and Development.

[24]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[25]  D. A. Kreutzer,et al.  Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. , 1998, Mutation research.

[26]  Ronald A. DePinho,et al.  The age of cancer , 2000, Nature.

[27]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[28]  J. Lindberg,et al.  Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. , 2013, European urology.